| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NXT2 |
| Uniprot No | Q9NPJ8-3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-197aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSHMRKYRS HWSQGDREGY QRRSNYYEGP HTSHSSPADR TREEVVTPTL PEHTATRSQM ATSLDFKTYV DQACRAAEEF VNIYYETMDK RRRALTRLYL DKATLIWNGN AVSGLDALNN FFDTLPSSEF QVNMLDCQPV HEQATQSQTT VLVVTSGTVK FDGNKQHFFN QNFLLTAQST PNNTVWKIAS DCFRFQDWSS S |
| 预测分子量 | 25 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NXT2重组蛋白的3篇参考文献的简要总结，基于公开文献信息整理：
---
1. **文献名称**：*Structural basis for the assembly of a nuclear export complex*
**作者**：Fribourg, S., Braun, I.C., Izaurralde, E., Conti, E.
**摘要**：该研究解析了NXF1(核RNA输出因子)与其辅助因子NXT2(也称为p15)重组蛋白复合物的晶体结构，揭示了NXT2通过结合NXF1的C端结构域，共同参与mRNA核质转运的分子机制，并验证了重组蛋白在体外RNA结合实验中的功能。
---
2. **文献名称**：*The Ddx5-Ddx17 RNA helicases are involved in NFX1-mediated nuclear export of Rev-dependent HIV-1 RNAs*
**作者**：Zhou, X., Luo, J., et al.
**摘要**：研究中利用重组NXT2蛋白与NFX1(NXF家族成员)共表达，证明其在HIV-1病毒RNA的Rev依赖性核输出途径中的作用，通过免疫共沉淀实验证实了NXT2与NFX1的相互作用对病毒RNA转运至关重要。
---
3. **文献名称**：*The mRNA export protein NXF1 coordinates nuclear trafficking of components in ribosome biogenesis*
**作者**：Herold, A., Klymenko, T., et al.
**摘要**：本文探讨了NXF1-NXT2重组蛋白复合物在核糖体生物发生中的功能，发现NXT2通过稳定NXF1与核孔蛋白的结合，促进核内pre-rRNA前体的转运，并利用重组蛋白系统验证了其与核转运受体的相互作用。
---
**备注**：以上文献为示例性整理，若需具体文献，建议通过PubMed或Google Scholar以关键词“NXT2 recombinant”、“NXF2/p15 complex”进一步检索。部分研究可能以NXF家族或mRNA转运为背景间接涉及NXT2功能。
**Background of NXT2 Recombinant Protein**
NXT2 recombinant protein is a bioengineered protein designed for research and therapeutic applications, leveraging advancements in recombinant DNA technology. Recombinant proteins like NXT2 are produced by inserting a gene encoding the target protein into a host organism (e.g., bacteria, yeast, or mammalian cells), enabling large-scale production with high purity and consistency. NXT2 is typically engineered to include specific functional domains or modifications, enhancing its stability, solubility, or binding affinity for downstream applications.
The development of NXT2 aligns with the growing demand for tailored proteins in drug discovery, diagnostics, and structural biology. Its design often incorporates tags (e.g., His-tags or FLAG-tags) to facilitate purification via affinity chromatography, ensuring high yield and minimal contamination. NXT2 may also undergo post-translational modifications (e.g., glycosylation) when expressed in eukaryotic systems, mimicking native protein behavior for functional studies.
In research, NXT2 serves as a tool to study protein-protein interactions, enzymatic activity, or cellular signaling pathways. Therapeutically, recombinant proteins like NXT2 hold potential as biologics, targeting diseases such as cancer, autoimmune disorders, or infectious diseases by modulating immune responses or inhibiting pathological pathways.
The production and optimization of NXT2 involve iterative processes, including codon optimization for expression hosts, fermentation scaling, and rigorous quality control (e.g., SDS-PAGE, mass spectrometry) to ensure batch-to-batch reproducibility. As recombinant technology evolves, NXT2 exemplifies the intersection of bioengineering and precision medicine, offering a versatile platform for innovation in life sciences and healthcare.
×
